Inmune Bio to Host Webinar Detailing XPro1595 Alzheimer's Registrational Pathway and Phase 3 Strategy

summarizeSummary

Inmune Bio announced a webinar to detail the registrational pathway and Phase 3 strategy for its XPro1595 program in early Alzheimer's disease, building on recent positive FDA feedback.

check_boxKey Events

• Webinar Announcement for XPro1595

  Inmune Bio will host a webinar on February 27, 2026, at 9:30 a.m. ET, to discuss the registrational pathway of XPro1595 for early Alzheimer's disease.

• FDA Alignment for Registrational Study

  The webinar will elaborate on the FDA feedback received post-Phase 2 MINDFuL trial, which supports advancing XPro1595 to a registrational study in Alzheimer's patients with inflammation biomarkers. This builds on the regulatory progress announced on February 13, 2026.

• Focus on Phase 3 and Global Partnership

  Key topics will include MINDFuL Phase 2 results, the rationale for the registrational study design, and the strategic roadmap to Phase 3, including securing a global partnership to maximize XPro1595's potential.

• Expert Clinical Speakers

  The webinar will feature presentations and discussions by Dr. Michael Woodward and Dr. Sharon Cohen, both internationally recognized Key Opinion Leaders in Alzheimer's disease research and site investigators in the MINDFuL trial.

auto_awesomeAnalysis

This 8-K announces a webinar to provide crucial details on the registrational pathway for XPro1595 in early Alzheimer's disease. This follows the significant FDA alignment announced on February 13, 2026, which supported advancement to a registrational study. The webinar will offer in-depth insights into the Phase 2 trial results, the specific FDA feedback received, and the strategic roadmap for Phase 3, including plans for a global partnership. For a company trading near its 52-week low, providing clarity and a detailed path forward for a key clinical asset like XPro1595 is important for investor confidence and understanding the company's future trajectory.